Send us Fan Mail

This is a deep-dive extended interview with the team behind ForCast Orthopedics — a company working to change how periprosthetic joint infection is treated. It's for orthopedic surgeons, arthroplasty specialists, and anyone interested in how a clinical idea becomes a medical device company.

The conversation brings together Dr. Jared Foran (CSO and co-founder), Dr. Leo Whiteside (the surgeon whose intraarticular infusion technique underlies the product), and Peter Noymer (CEO). Together they trace the origin of the idea from residency-era frustration with antibiotic elution curves, through multiple failed prototypes, to the current catheter-based system designed to make Whiteside's technique practical and scalable.

The discussion covers the pharmacokinetic rationale for intraarticular infusion, the clinical and economic case for tackling PJI more aggressively, the regulatory strategy including Orphan Drug and QIDP designations, what it takes to pitch early-stage med tech to investors, and what ForCast's scientific advisory board actually does for product strategy. If you're curious about what a surgeon-founded company looks like from the inside — the pivots, the regulatory burden, the reimbursement complexity, and the moment the team knew the idea was worth building — this is the conversation.

Learn more about ForCast Orthopedics: https://forcastortho.com

⏱️ Chapters:
00:00 Introductions
01:44 The clinical origin of the idea
02:57 Why intraarticular infusion works: the pharmacokinetic argument
06:00 What ForCast brought to Leo's technique
07:34 Peter's personal and professional motivation
08:46 The emotional spark that drove Jared to pursue it
10:35 Early questions and challenges developing the technique
13:30 Success rates and the evidence base
14:41 From good idea to viable company: the business case
16:49 Surprising early prototype results and what they revealed
19:15 Common mistakes new innovators make
20:00 How to approach investors before clinical proof exists
22:06 Orphan Drug and QIDP designations explained
25:21 FDA endpoints and what has to be proven
26:08 Balancing regulatory requirements with clinical reality
27:03 How the scientific advisory board shapes product strategy
28:53 What makes surgeons trust or resist a new technology
30:43 Feedback from early adopters
33:05 The kit that surgeons have been waiting for
33:25 The biggest barrier to hospital adoption
35:20 What true success looks like for ForCast
37:20 Timeline for widespread adoption
37:48 The hardest part of the journey
38:18 What "from idea to market" means after living it
39:14 Advice for the surgeon with an idea on a napkin
41:07 What has been most fulfilling
43:20 Closing thoughts

Listen to the AHF Podcast on your preferred platform:

Buzzsprout: https://ahfpodcast.buzzsprout.com
Apple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487
Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHc
LinkedIn: https://www.linkedin.com/showcase/ahf-podcast
YouTube: https://www.youtube.com/@anteriorhipfoundation
Homepage: https://anteriorhipfoundation.com

This podcast is intended for educational and informational purposes only. The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.

#AnteriorHipFoundation #AHFPodcast #ForCastOrthopedics #PeriprostheticJointInfection #PJI #IntraArticularInfusion #MedicalDeviceInnovation #OrthopedicInfection #TotalHipArthroplasty #TotalKneeArthroplasty #ArthroplastyInfection #MedTechStartup #OrphanDrug

FITM: The Full Conversation with ForCast Orthopedics